Author/Authors :
Ghafari, Somayeh Faculty of Pharmacy - Tehran University of Medical Sciences - Tehran, Iran , Dashti-Khavidaki, Simin Faculty of Pharmacy - Tehran University of Medical Sciences - Tehran, Iran , Khatami, Mohammadreza Nephrology Research Center - Tehran University of Medical Sciences - Tehran, Iran , Ghahremani, Mohammad-Hossein Tehran University of Medical Sciences - Tehran, Iran , Seyednejad, Seyed-Afshin Department of Pharmacology and Toxicology - Faculty of Pharmacy - Tehran University of Medical Sciences - Tehran, Iran , Beh-Pajooh, Abbas Department of Pharmacology and Toxicology - Faculty of Pharmacy - Tehran University of Medical Sciences - Tehran, Iran
Abstract :
Tacrolimus is the cornerstone of immunosuppressive
therapy in organ transplantation with variable inter-individual
pharmacokinetics. This study assessed the relationship between
CYP3A5/3A4 polymorphisms and tacrolimus dose requirement as
well as 6-month transplant outcomes in Iranian kidney transplant
recipients.CYP3A5 genetic polymorphism is significantly associated
with required tacrolimus dose. After achieving desired tacrolimus
blood level, although some transplant outcomes such as the incidence
of clinically suggested acute rejection and time to first rejection were
different between CYP3A5 expressers and non-expressers, however,
other clinical outcomes did not differ between groups. Therefore, it
is not the time to routinely assess kidney transplant recipients for
CYP3A5 genetic polymorphism before transplantation.
Keywords :
tacrolimus , polymorphism , kidney transplantation , CYP3A
